

ASX ANNOUNCEMENT

9 November 2022

Correction to Appendix 3Y



Little Green Pharma Ltd (ASX: LGP, “LGP” or the “Company”) wishes to correct an administrative error in the Appendix 3Y issued on 6 September 2022 in respect of the securities held by Dr. Neale Fong.

On 7 December 2021, the Company issued an Appendix 2A which included a quantity of ordinary shares resulting from the conversion of 75,458 share rights held by Dr. Fong. While that Appendix 2A correctly stated the number of ordinary shares to Dr. Fong, due to administrative oversight the Company did not also issue an Appendix 3Y identifying the conversion of these securities in Dr. Fong’s holdings.

Accordingly, the Appendix 3Y concerning Dr. Fong’s holdings issued subsequently on 6 September 2022 did not properly reflect the conversion of these share rights. The Company therefore wishes to issue the attached revised Appendix 3Y which correctly states the number of ordinary shares resulting from these converted share rights and held by Dr. Fong as at 6 September 2022.

Further to the above, the Company provides the following information in respect of its compliance with Listing Rules 3.19A.2 and 3.19B:

- The Company refers to the explanation given above in relation to the delay providing the Appendix 3Y to ASX.
- The Company believes its present arrangements concerning the disclosure of information by directors and required by the entity to give ASX completed Appendices 3X, 3Y and 3Z is adequate, and in the present case all the required information was provided by Dr. Fong. The Company also has policies to assist it with complying with its continuous and other disclosure obligations including the Company’s Securities Trading Policy and Continuous Disclosure Policy.
- In the present case, the omission in providing an Appendix 3Y in December 2021 was due to an administrative oversight, following detection of which the Company has undertaken a review of its procedures to ensure that all future Appendices 3X, 3Y and 3Z are issued on time and contain the correct information.

ENDS
BY ORDER OF THE BOARD



Alistair Warren
Company Secretary



For further information please contact:

Alistair Warren
Company Secretary

Little Green Pharma
E: a.warren@lgp.global
T: +61 8 6280 0050

Fleta Solomon
Chief Executive Officer

Little Green Pharma
E: f.solomon@lgp.global
T: +61 8 6280 0050

About Little Green Pharma

Little Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.

The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, being a 21,500m² cultivation and 4,000m² GMP manufacturing facility capable of producing over 30 tonnes of medicinal cannabis biomass per annum located in Denmark (EU) and an indoor cultivation and manufacturing facility located in Western Australia capable of producing ~3 tonnes of medicinal cannabis biomass per annum.

Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: www.littlegreenpharma.com

Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email. This will ensure efficient communication during COVID-19 while also helping to reduce our costs and environmental footprint.

To easily update your communication preferences, visit: www.computershare.com.au/easyupdate/lgp

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Little Green Pharma Ltd
ACN	615 586 215

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Neale William Fong
Date of last notice	6 September 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Riverpalm Pty Ltd ATF NW Fong Family Trust - Dr Fong is a director Dr Neale Fong ATF Damblock Trust - Dr Fong is a trustee
Date of change	6 September 2022
No. of securities held prior to change	Riverpalm Pty Ltd <NW Fong Family Trust> 296,154 Ordinary shares Dr Neale Fong <Damblock Trust> 791,871 Ordinary shares 185,000 Retention Share Rights
Class	Retention Share Rights
Number acquired	35,000

* The previous balance reported on 12 March 2021 did not include 46,154 shares purchased through the Company's Share Purchase Plan on 11 March 2021 which was disclosed in the Share Purchase Plan Offer Booklet dated 15 February 2021.

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Number disposed	Nil
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil
No. of securities held after change	Riverpalm Pty Ltd <NW Fong Family Trust> 296,154 Ordinary shares Dr Neale Fong <Damblock Trust> 791,871 Ordinary shares 220,000 Retention Share Rights
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issue of incentive securities approved at AGM

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

* The previous balance reported on 12 March 2021 did not include 46,154 shares purchased through the Company's Share Purchase Plan on 11 March 2021 which was disclosed in the Share Purchase Plan Offer Booklet dated 15 February 2021.

+ See chapter 19 for defined terms.